Literature DB >> 18551075

OX40 controls islet allograft tolerance in CD154 deficient mice by regulating FOXP3+ Tregs.

Ming Chen1, Xiang Xiao, Gulcin Demirci, Xian Chang Li.   

Abstract

The role of OX40 in the islet allograft tolerance, especially in the absence of CD154 costimulation, remains poorly defined. In the present study, we used CD154 deficient mice to critically examine the role of OX40 in the activation of T effector cells and Foxp3+ Tregs and the effect of blocking OX40 on the induction of islet allograft tolerance. We found that blocking OX40 costimulation in CD154 deficient mice induced donor specific tolerance but stimulating OX40 resulted in prompt islet allograft rejection. We also found that OX40 differentially regulates T effector cells and Foxp3+ Tregs, OX40 signaling mediates proliferation of CD154 deficient T effector cells but blocks the induction and suppressor functions of Foxp3+ Tregs. Our data suggest that the role of OX40 in the induction of islet allograft tolerance involves modifying not only the T effector cells but also the Foxp3+ Tregs in CD154 deficient mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18551075     DOI: 10.1097/TP.0b013e3181726987

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  20 in total

1.  OX40 ligand fusion protein delivered simultaneously with the BCG vaccine provides superior protection against murine Mycobacterium tuberculosis infection.

Authors:  Robert J Snelgrove; Megan M Cornere; Lorna Edwards; Belinda Dagg; James Keeble; Angela Rodgers; Daphne E Lyonga; Graham R Stewart; Douglas B Young; Barry Walker; Tracy Hussell
Journal:  J Infect Dis       Date:  2012-02-07       Impact factor: 5.226

2.  Urinary cell levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and acute rejection of human renal allografts.

Authors:  Cheguevara Afaneh; Thangamani Muthukumar; Michelle Lubetzky; Ruchuang Ding; Catherine Snopkowski; Vijay K Sharma; Surya Seshan; Darshana Dadhania; Joseph E Schwartz; Manikkam Suthanthiran
Journal:  Transplantation       Date:  2010-12-27       Impact factor: 4.939

Review 3.  Molecular mechanism and function of CD40/CD40L engagement in the immune system.

Authors:  Raul Elgueta; Micah J Benson; Victor C de Vries; Anna Wasiuk; Yanxia Guo; Randolph J Noelle
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 4.  Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells.

Authors:  Hélène Bour-Jordan; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

5.  Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interaction.

Authors:  Yun Song; Emilio Margolles-Clark; Allison Bayer; Peter Buchwald
Journal:  Br J Pharmacol       Date:  2014-11       Impact factor: 8.739

Review 6.  Transplant research in nonhuman primates to evaluate clinically relevant immune strategies in organ transplantation.

Authors:  Zachary Fitch; Robin Schmitz; Jean Kwun; Bernhard Hering; Joren Madsen; Stuart J Knechtle
Journal:  Transplant Rev (Orlando)       Date:  2019-04-05       Impact factor: 3.943

7.  The upregulated expression of OX40/OX40L and their promotion of T cells proliferation in the murine model of asthma.

Authors:  Wei Lei; Da-Xiong Zeng; Can-Hong Zhu; Gao-Qin Liu; Xiu-Qin Zhang; Chang-Guo Wang; Qin Wang; Jian-An Huang
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

Review 8.  The significance of OX40 and OX40L to T-cell biology and immune disease.

Authors:  Michael Croft; Takanori So; Wei Duan; Pejman Soroosh
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

9.  OX40 costimulation prevents allograft acceptance induced by CD40-CD40L blockade.

Authors:  Bryna E Burrell; Guanyi Lu; Xian C Li; D Keith Bishop
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

Review 10.  The role of TNF superfamily members in T-cell function and diseases.

Authors:  Michael Croft
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.